Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. - Wikidata - wikimedia - TriplyDB

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

http://www.wikidata.org/entity/Q40678042

about

Drug transport in brain via the cerebrospinal fluid Gene therapy in Parkinson's disease: rationale and current status Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression Available and emerging treatments for Parkinson's disease: a review Parkinson's disease: gene therapies Multiple system atrophy: a clinical and neuropathological perspective Parkinson's disease gene therapy: success by design meets failure by efficacy Stem cell transplantation for motor neuron disease: current approaches and future perspectives Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease Towards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans.GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease Crossroads in GDNF therapy for Parkinson's disease Permeabilization of the blood-brain barrier via mucosal engrafting: implications for drug delivery to the brain GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse model CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo.Site of deep brain stimulation and jaw velocity in Parkinson disease.Clinical application of neurotrophic factors: the potential for primary auditory neuron protection Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease.Neuroregeneration in neurodegenerative disorders.Safety Evaluation of CNS Administered Biologics-Study Design, Data Interpretation, and Translation to the Clinic.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles.Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects.Current status of cell therapies in stroke.Zebrafish GDNF and its co-receptor GFRα1 activate the human RET receptor and promote the survival of dopaminergic neurons in vitro Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy The effect of deep brain stimulation randomized by site on balance in Parkinson's disease The stem cell secretome and its role in brain repair.Naringin: a protector of the nigrostriatal dopaminergic projection.Glial cell line-derived neurotrophic factor gene therapy ameliorates chronic hyperprolactinemia in senile rats.Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.

P2860

Q21092913-4673B708-4E4B-4858-85A3-D0E5FF999987 Q22241423-2289A275-3EE2-4302-87A5-E2725F775B5D Q24289526-FB31CA51-BD76-4665-8BF0-46F834012CB5 Q24339450-E58036BE-873A-402F-8872-ED6243349D97 Q24633444-35BCE512-1397-4B44-AEF5-1CA7BEF34D75 Q26824184-3D6FD054-5271-4335-A47F-3FDC3702F26F Q26829838-8836F9EE-665B-4164-9394-7306D352AC77 Q26851325-10EFB1D1-E4DC-4F9D-836B-DF260FAE873B Q26995278-9C36E115-673D-4C03-AFEE-80352FCE4321 Q27002651-6C680DA5-905A-44AA-B250-6EEFAB594024 Q27023715-420F06AE-057A-4683-89A9-635120C7EB5F Q27320553-F04EDC56-F3D0-4095-884D-F6EB5BEFCBD5 Q28067169-937762CC-B749-43BA-A57D-A2D85F36D202 Q28088320-06707DE4-1081-49E2-B954-88935CB0D2BA Q28296616-276630BD-2C91-4728-9395-CE41A90DA22B Q28486860-8F713CB8-AA81-4E2F-BC61-1C128608134D Q28543023-E54F4A73-C46F-43E0-B794-F67272D76216 Q28732722-6C3B85D2-8471-4B43-8BB1-3310A4D8CE04 Q30387126-A94F453A-1E6F-4AB4-949C-95AB15C6A4B5 Q30459981-AC480C49-D739-42BB-9ED8-EBD80117751C Q30499419-AB37E291-4C32-488F-8810-7EE9D68681B0 Q30581632-D0A64FAC-7D43-4766-BA51-61D74FB3072D Q30624869-B8DE55EE-BB49-4F80-A706-F0AC05654702 Q30846057-1B7B5293-E4D9-4268-84BF-5B1766ACCAA6 Q31020342-D7B594A7-5BEB-4B62-8188-E3730181434F Q31111228-308319A9-7ECD-43C9-99D9-433C0A020C94 Q33260250-23425EF0-C77A-401E-A8FB-584FF007E64C Q33327584-235E527D-B3ED-43AB-A012-55BD9A3887A1 Q33517934-001485A8-5DCF-4CCF-8D42-9D47E7C25BAE Q33600773-0BE38447-223E-4873-9D26-E2D9E0F16F21 Q33614825-59649BA6-9931-4C71-8CE4-A93DD40B6FEB Q33632891-41932AE0-6F77-4B77-9D6F-51F440D42215 Q33700352-9A14DFA6-78FF-487F-8791-D795192A23F1 Q33756645-10637D20-42FF-41DA-883C-D9BA82CDE6CE Q33771698-94381297-6420-4532-AFBE-AA2C1CD7C59C Q33787324-7BAE5796-1C76-4649-9FAD-43CCADDD36C0 Q33787660-4B4A3E7C-ABC9-4763-A491-D8FCC7ED8653 Q33807060-71243100-5C77-4961-B5AD-9F3B676699F4 Q33819946-16EA0F5E-4624-4F17-B544-2E09DBD27C65 Q33851241-1306BC95-E6B6-4337-9A3C-F5399C0E5BB7

P2860

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

http://www.wikidata.org/entity/Q40678042

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Randomized, double-blind trial ...... rotrophic factor (GDNF) in PD.

@en

type

label

Randomized, double-blind trial ...... rotrophic factor (GDNF) in PD.

@en

prefLabel

Randomized, double-blind trial ...... rotrophic factor (GDNF) in PD.

@en

P1433

Q40678042-7DF0BC35-3B73-4270-8AEA-66DD4DA07C9D

P1476

Q40678042-15C3C26B-5068-4388-96BC-2A60C2422CA4

P2093

Q40678042-00C6DAB8-30CB-4095-B07E-96D4D96A8815

Q40678042-30108CD6-00B6-403C-9AED-3AD8CDB06171

Q40678042-418D911F-0200-4C06-8F51-B25CE6AB19D7

Q40678042-53E6077C-A851-447F-9017-B31B7CD0EA11

Q40678042-6F4DE60A-585C-46A0-B83A-75B292DE5932

Q40678042-7100C353-B715-46D1-9596-DFBDE91F0975

Q40678042-83A9C434-28F3-4985-A796-D55E03C2C0B4

Q40678042-88B4A313-7A4F-47FF-801D-516F2C1F1FE0

Q40678042-970A1239-B082-49AB-8298-7A13E73FA5DF

Q40678042-AF81B84E-636F-4C41-B643-B0B9B57D8B9E

P304

Q40678042-87419B2E-EDC4-476F-B111-EEB8158D8D02

P31

Q40678042-3D46EE08-8783-48C3-9E3D-135A27CAE19C

P356

Q40678042-C72AF4E5-C972-49CE-9AD0-D9BAA57F208E

P407

Q40678042-84F66F05-3C8D-42A0-98DE-B1D16F54E119

P433

Q40678042-9E57BC7B-96D9-4AE0-947B-8D23683AC06E

P478

Q40678042-F20919F6-FCCB-4D3A-B0C6-934090D06CDA

P50

Q40678042-31117F56-43AA-4A12-B8AC-442DF562D286

P577

Q40678042-A09B6433-EC26-4F32-AF7E-A7681B472158

P698

Q40678042-7C256FB2-D4DE-4DE0-9E51-550A8969DA6C

P356

P1433

P1476

Randomized, double-blind trial ...... urotrophic factor (GDNF) in PD

@en

P2093

A M Lozano

http://www.w3.org/2001/XMLSchema#string

C L Comella

http://www.w3.org/2001/XMLSchema#string

E R Laws

http://www.w3.org/2001/XMLSchema#string

G F Wooten

http://www.w3.org/2001/XMLSchema#string

ICV GDNF Study Group. Implante ...... ne-derived neurotrophic factor

http://www.w3.org/2001/XMLSchema#string

J G Nutt

http://www.w3.org/2001/XMLSchema#string

J Jankovic

http://www.w3.org/2001/XMLSchema#string

K J Burchiel

http://www.w3.org/2001/XMLSchema#string

M Stacy

http://www.w3.org/2001/XMLSchema#string

R D Penn

http://www.w3.org/2001/XMLSchema#string

P304

69-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.60.1.69

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12525720

http://www.w3.org/2001/XMLSchema#string